EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments

– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU^™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 –